Researchers in Belgium have found that MR elastography is more accurate than a blood test commonly used in the noninvasive staging of liver fibrosis. The study adds weight to clinical literature that suggests MR elastography could replace biopsy.
Researchers in Belgium have found that MR elastography is more accurate than a blood test commonly used in the noninvasive staging of liver fibrosis. The study adds weight to clinical literature that suggests MR elastography could replace biopsy.
Dr. Laurent Huwart and colleagues from the radiology department at the Catholic University of Louvain in Brussels enrolled 88 patients with suspected chronic liver disease who underwent MR elastography and the aspartate aminotransferase-to-platelet ratio index (APRI) exam within two days of liver biopsy. They found that MR elastography distinguished several stages of fibrosis more accurately than did the APRI blood testing. They published their findings in the November issue of Radiology.
Multicenter Study Shows Merits of AI-Powered Ultrasound Assessment for Detecting Ovarian Cancer
January 3rd 2025Adjunctive AI offered greater than seven percent increases in sensitivity, specificity, and accuracy for ultrasound detection of ovarian cancer in comparison to unassisted clinicians who lacked ultrasound expertise, according to findings from new international multicenter research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.